There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …

Concurrent with US Food and Drug Administration (FDA) approval of the first therapeutic
cancer vaccine, a wide spectrum of other cancer vaccine platforms that target a diverse …

Cancer vaccines have been shown clinically to drive tumor-reactive cell activation,
proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

The development of cancer vaccines has been intensively pursued over the past 50 years
with modest success. However, recent advancements in the fields of genetics, molecular …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

Background: Cancer vaccines are a unique approach to cancer therapy. They exert an
antitumor effect by engaging the host immune response, and have great potential for …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

Therapeutic cancer vaccines have the potential of being integrated in the therapy of
numerous cancer types and stages. The wide spectrum of vaccine platforms and vaccine …

In recent years, there has been a surge of interest in tumor microenvironment-associated
cancer vaccine therapies. These innovative treatments aim to activate and enhance the …